



Corporate Fact Sheet

EMERGENT BIOSOLUTIONS

We are a global specialty biopharmaceutical company dedicated to one simple mission — **to protect and enhance life**. We develop, manufacture, and deliver a portfolio of medical countermeasures for civilian and military populations that address intentional, accidental and naturally emerging public health threats, as well as emerging infectious diseases. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025.

OPERATIONS

Headquarters: Gaithersburg, MD
Manufacturing Facilities: United States, Canada
Product Development Sites: United States, Canada
Services: Contract manufacturing
Product Portfolio: Vaccines, antibody therapeutics, and antimicrobials focused on infectious diseases, as well as medical devices for chemical threats

PORTFOLIO AS OF AUGUST 2016

PRODUCT / PRODUCT CANDIDATE	DISEASE / THERAPEUTIC AREA	TYPE	STAGE
BioThrax® Anthrax Vaccine Adsorbed	Anthrax	Vaccine	Marketed ■ ■ ■ ■ ■
RSDL® Reactive Skin Decontamination Lotion Kit	Chemical Decontamination	Medical Device	Marketed ■ ■ ■ ■ ■
VIGIV Vaccinia Immune Globulin Intravenous (Human)	Smallpox ¹	Therapeutic	Marketed ■ ■ ■ ■ ■
BAT® Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)	Botulism	Therapeutic	Marketed ■ ■ ■ ■ ■
Anthrasil™ Anthrax Immune Globulin Intravenous (Human)	Anthrax	Therapeutic	Marketed ■ ■ ■ ■ ■
NuThrax™ anthrax vaccine adsorbed with CPG 7909 adjuvant	Anthrax	Vaccine	Phase 3 ² ■ ■ ■ ■ ■
PreviThrax™ purified recombinant protective antigen anthrax vaccine adsorbed with CPG 7909 adjuvant	Anthrax	Vaccine	Phase 1 ² ■ ■ ■ ■ ■
VAX161C³	Pandemic Influenza	Vaccine	Phase 1 ■ ■ ■ ■ ■
UV-4B	Dengue	Therapeutic	Phase 1 ■ ■ ■ ■ ■

Other product candidates focused on public health threats and emerging infectious diseases



¹ Indicated for adverse events associated with the Smallpox vaccine
² Status reflects both clinical and nonclinical development under the FDA Animal Rule
³ Pandemic Influenza vaccine licensed from VaxInnate



PLATFORMS & TECHNOLOGIES

PLATFORM / TECHNOLOGY DESCRIPTION	PRECLINICAL PIPELINE	CLINICAL PIPELINE	MARKETED PRODUCTS
Hyperimmunes Human – Purified gamma globulin (IgG) containing polyclonal antibodies to specific antigen(s) obtained from fractionation of human plasma	—	—	Anthrasil™ VIGIV
Equine – Purified immune globulin fragments derived from polyclonal antibodies to specific antigen(s) obtained from fractionation of equine plasma	—	—	BAT®
Emergard™ (auto-injector) Military-grade auto-injector device	—	—	—
Antivirals Broad-spectrum antiviral iminosugars with a mechanism of action that inhibits a host glycosylation pathway resulting in misfolded viral glycoproteins subsequently leading to reduced viral infectivity	—	Dengue	—
Antibacterials EV-035 series of molecules with a novel 4-oxoquinolizine antibacterial backbone showing activity against quinolone-resistant bacterial strains	—	—	—
MVAator™ (modified vaccinia virus Ankara vector) Recombinant, live, attenuated viral vector for the development of vaccines	Respiratory Syncytial Virus (RSV) Universal flu Ebola	—	—

RECENT BUSINESS HIGHLIGHTS

- ▶ Spin-Off of Aptevo Therapeutics Approved by Emergent BioSolutions' Board of Directors, Record and Dividend Distribution Dates and Distribution Ratio Set
- ▶ BARDA Task Order Valued at Up to \$21.9 Million Received to Develop and Manufacture a Zika Vaccine
- ▶ Solicitation Notices Issued by the U.S. Government Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of Anthrax Vaccines
- ▶ Supplemental Biologics License Application (sBLA) Accepted by the FDA for Large-Scale Manufacturing of BioThrax in Building 55 and Pre-Approval Inspection Completed
- ▶ Orphan Drug Status Received From the FDA for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease
- ▶ Form 10 Registration Statement Filed With the SEC for the Planned Spin-Off of Aptevo Therapeutics
- ▶ Emergard™ Auto-Injector Platform for Nerve Agent Antidote Delivery Selected by U.S. Department of Defense and Battelle for Testing and Development

FINANCIAL HIGHLIGHTS

	Total Revenue (dollars in millions)	Net Income (dollars in millions)	Assets (dollars in millions)	EBITDA (dollars in millions)
2015	523	63	1044	130
2014	450	37	939	92
2013	313	31	627	63
2012	282	24	564	49
2011	273	23	547	48

Our historical results for any prior period are not necessarily indicative of results to be expected in any future period.

CONTACT INFORMATION

Corporate
400 Professional Drive, Suite 400
Gaithersburg, MD 20879 USA
Tel: 240-631-3200 Fax: 240-631-3203

Business Development: Darren Buchwald, BD@ebsi.com
Investor Relations: Robert Burrows, burrowsr@ebsi.com
Corporate Communications: Tracey Schmitt Lintott, schmittt@ebsi.com
www.emergentbiosolutions.com www.biothrax.com www.rsdll.com

